Page last updated: 2024-08-24

telmisartan and Triple Negative Breast Neoplasms

telmisartan has been researched along with Triple Negative Breast Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, W; Dang, C; Diao, D; Li, M; Wang, Y; Xie, X; Zhang, X	1

Other Studies

1 other study(ies) available for telmisartan and Triple Negative Breast Neoplasms

Article	Year
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan. Cancer biology & therapy, 2020, 12-01, Volume: 21, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Metabolic Syndrome; Obesity; Rats; Rats, Wistar; Telmisartan; Triple Negative Breast Neoplasms	2020

Article

Year

Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.

Cancer biology & therapy, 2020, 12-01, Volume: 21, Issue:12

Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Metabolic Syndrome; Obesity; Rats; Rats, Wistar; Telmisartan; Triple Negative Breast Neoplasms

2020